Immunotherapy

Advertisement

Advertisement

Cristina Saura, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

G. Thomas Budd, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Recent

ASCO-SITC 2019: HER2-Targeted Vaccine Plus Trastuzumab in Breast Cancer

Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’

Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer Approved by the FDA

2019 ASCO-SITC: Tumor Growth Rate and Outcomes With Nivolumab in Head and Neck Cancer

Published

Medical Literature

Immunotherapy for Patients With NSCLC and HIV Infection

JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer

New Combination Therapy for NSCLC Tested in Phase II Trial

Ovarian Carcinosarcoma: Update on a Rare Malignancy

Ongoing

JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?

Immunotherapy for cSCC: How, Why, and When (login required)

Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy

Available

Clinical Trials

Center for Immunotherapy Clinical Research Trials

Cancer Research Institute Immunotherapy Clinical Trials

ClinicalTrials.gov Immunotherapy

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

Sections

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.